Pharmacology News

Patients with atherosclerotic CVD had low levels of lipid-lowering therapy intensification and most did not achieve LDL goals at 2 years, according to new data from the GOULD registry.

Empagliflozin reduced CV death or HF hospitalization compared with placebo in patients with HF with preserved ejection fraction, regardless of diabetes status, according to topline results of the EMPEROR-Preserved trial.

Many physicians are reluctant to prescribe medical cannabis amid its uncertain legal status and preliminary, sometimes contradictory, clinical data on its safety and benefits.

Among patients who experienced a moderate to severe migraine attack, IV treatment with Vyepti shortened time to headache and symptom resolution compared with placebo, according to results from a randomized clinical trial.

Amid a lawsuit battle concerning a Humira biosimilar product between AbbVie and Alvotech, experts predict that the market will explode as greater competition begins to erode Humira’s profits.

The use of statins in patients with recently diagnosed type 2 diabetes reduced incidence of CVD and death, particularly in older and adherent patients, according to a study.

A “marked decrease” in respiratory virus detections correlated with a 79% reduction in ambulatory antibiotic prescribing rates for respiratory tract infections during the COVID-19 pandemic, researchers of a pre-post study wrote.

Sotagliflozin increased the number of days alive and out of the hospital compared with placebo among patients with type 2 diabetes at high risk for intermittent hospitalization due to worsening heart failure, data show.

A survey of patients with insomnia who participated in two phase 3 trials investigating daridorexant reported that “improved daytime functioning” was the most important treatment outcome for their condition.

The AMA has adopted a new policy that discourages health insurance companies from offering financial incentives to patients for switching medications, according to the organization.